BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21206980)

  • 1. Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.
    Yoshiba S; Iwase M; Kurihara S; Uchida M; Kurihara Y; Watanabe H; Shintani S
    Oncol Rep; 2011 Mar; 25(3):645-52. PubMed ID: 21206980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
    Uchida M; Iwase M; Takaoka S; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
    Int J Oncol; 2007 May; 30(5):1163-71. PubMed ID: 17390018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
    Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
    Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway.
    Inoue T; Shiraki K; Fuke H; Yamanaka Y; Miyashita K; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Anticancer Drugs; 2006 Mar; 17(3):261-8. PubMed ID: 16520654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
    Zhu H; Guo W; Zhang L; Wu S; Teraishi F; Davis JJ; Dong F; Fang B
    Cancer Biol Ther; 2005 Jul; 4(7):781-6. PubMed ID: 16082182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
    Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
    Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway.
    Zhu W; Zhan D; Wang L; Ma D; Cheng M; Wang H; Zhao J; Cai Y; Cheng Z
    Oncol Rep; 2016 Aug; 36(2):845-52. PubMed ID: 27277541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.
    Yoshida T; Shiraishi T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(13):5662-7. PubMed ID: 15994939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
    Chen JJ; Chou CW; Chang YF; Chen CC
    J Immunol; 2008 Jun; 180(12):8030-9. PubMed ID: 18523266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
    Seol DW
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
    Li X; Huang T; Jiang G; Gong W; Qian H; Zou C
    Biochem Biophys Res Commun; 2013 Sep; 439(2):179-86. PubMed ID: 23994633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
    BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
    Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
    Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
    Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
    Li W; Zhang X; Olumi AF
    Cancer Res; 2007 Mar; 67(5):2247-55. PubMed ID: 17332355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation.
    Paul T; Banerjee A; Reddy SVB; Mahato SK; Biswas N
    Anticancer Drugs; 2019 Feb; 30(2):167-178. PubMed ID: 30418193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
    He Q; Huang Y; Sheikh MS
    Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.